

# Roland B Walter

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/6830360/roland-b-walter-publications-by-year.pdf>

**Version:** 2024-04-20

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

302  
papers

9,808  
citations

49  
h-index

90  
g-index

330  
ext. papers

11,899  
ext. citations

4.9  
avg, IF

6.32  
L-index

#	Paper	IF	Citations
302	Where do we stand with radioimmunotherapy for acute myeloid leukemia?. <i>Expert Opinion on Biological Therapy</i> , <b>2022</b> , 1-7	5.4	0
301	Intensive chemotherapy for acute myeloid leukemia relapse after allogeneic hematopoietic cell transplantation.. <i>American Journal of Hematology</i> , <b>2022</b> ,	7.1	0
300	Technical Aspects of Flow Cytometry-based Measurable Residual Disease Quantification in Acute Myeloid Leukemia: Experience of the European LeukemiaNet MRD Working Party.. <i>HemaSphere</i> , <b>2022</b> , 6, e676	0.3	3
299	Selection of Patients for Individual Acute Myeloid Leukemia Therapies. <i>Hematologic Malignancies</i> , <b>2021</b> , 69-75	0	
298	Safety and Efficacy from a Phase 1b/2 Study of IMG632 in Combination with Azacitidine and Venetoclax for Patients with CD123-Positive Acute Myeloid Leukemia. <i>Blood</i> , <b>2021</b> , 138, 372-372	2.2	5
297	Development of Astatine-211 (211At)-Based Anti-CD123 Radioimmunotherapy for Acute Leukemias and Other CD123+ Hematologic Malignancies. <i>Blood</i> , <b>2021</b> , 138, 3341-3341	2.2	1
296	Elihu H. Estey, MD: leukemia expert, statistician, and gentle soul (July 15, 1946-October 8, 2021). <i>Leukemia</i> , <b>2021</b> , 35, 3619-3621	10.7	
295	Targeting the Membrane-Proximal C2-Set Domain of CD33 for Improved CD33-Directed CAR T Cell Therapy. <i>Blood</i> , <b>2021</b> , 138, 2776-2776	2.2	
294	Financial Implications of Early Hospital Discharge After AML-Like Induction Chemotherapy: A 4-Year Retrospective Analysis. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , <b>2021</b> , 1-10	7.3	1
293	Comparative analysis of infectious complications with outpatient inpatient care for adults with high-risk myeloid neoplasm receiving intensive induction chemotherapy. <i>Leukemia and Lymphoma</i> , <b>2021</b> , 1-10	1.9	0
292	2021 Update Measurable Residual Disease in Acute Myeloid Leukemia: European LeukemiaNet Working Party Consensus Document. <i>Blood</i> , <b>2021</b> ,	2.2	33
291	Survival of patients with newly diagnosed high-grade myeloid neoplasms who do not meet standard trial eligibility. <i>Haematologica</i> , <b>2021</b> , 106, 2114-2120	6.6	3
290	Measurable residual disease as a biomarker in acute myeloid leukemia: theoretical and practical considerations. <i>Leukemia</i> , <b>2021</b> , 35, 1529-1538	10.7	15
289	Effect of post-treatment MRD status on subsequent outcomes according to chemotherapy intensity in acute myeloid leukemia (AML). <i>Leukemia and Lymphoma</i> , <b>2021</b> , 62, 1532-1535	1.9	1
288	Acute myeloid leukemia measurable residual disease detection by flow cytometry in peripheral blood vs bone marrow. <i>Blood</i> , <b>2021</b> , 137, 569-572	2.2	9
287	Optimal dosing of cytarabine in induction and post-remission therapy of acute myeloid leukemia. <i>Leukemia</i> , <b>2021</b> , 35, 295-298	10.7	1
286	Budget Impact Analysis of Gemtuzumab Ozogamicin for the Treatment of CD33-Positive Acute Myeloid Leukemia. <i>Pharmacoeconomics</i> , <b>2021</b> , 39, 121-131	4.4	2

285	Flotetuzumab as salvage immunotherapy for refractory acute myeloid leukemia. <i>Blood</i> , <b>2021</b> , 137, 751-762	77
284	Comparison of outpatient care following intensive induction versus post-remission chemotherapy for adults with acute myeloid leukemia and other high-grade myeloid neoplasms. <i>Leukemia and Lymphoma</i> , <b>2021</b> , 62, 234-238	1.9 2
283	Characteristics and outcome of patients with acute myeloid leukaemia and t(8;16)(p11;p13): results from an International Collaborative Study. <i>British Journal of Haematology</i> , <b>2021</b> , 192, 832-842	4.5 4
282	Targeting the membrane-proximal C2-set domain of CD33 for improved CD33-directed immunotherapy. <i>Leukemia</i> , <b>2021</b> , 35, 2496-2507	10.7 1
281	Predicting severe toxicities with intensive induction chemotherapy for adult acute myeloid leukemia: analysis of SWOG Cancer Research Network trials S0106 and S1203. <i>Leukemia and Lymphoma</i> , <b>2021</b> , 62, 1774-1777	1.9
280	Recent Advancements in Hematology: Knowledge, Methods and Dissemination, Part 2. <i>Hemato</i> , <b>2021</b> , 2, 79-88	0.2
279	Outcomes of Hematopoietic Cell Transplantation in Patients with Mixed Response to Pretransplantation Treatment of Confirmed or Suspected Invasive Fungal Infection. <i>Transplantation and Cellular Therapy</i> , <b>2021</b> , 27, 684.e1-684.e9	2
278	Chimeric Antigen Receptor (CAR)-Modified Immune Effector Cell Therapy for Acute Myeloid Leukemia (AML). <i>Cancers</i> , <b>2020</b> , 12,	6.6 2
277	Camidanlumab tesirine, an antibody-drug conjugate, in relapsed/refractory CD25-positive acute myeloid leukemia or acute lymphoblastic leukemia: A phase I study. <i>Leukemia Research</i> , <b>2020</b> , 95, 106385	2.7 14
276	The Bruton <sup>®</sup> tyrosine kinase inhibitor ibrutinib abrogates bispecific antibody-mediated T-cell cytotoxicity. <i>British Journal of Haematology</i> , <b>2020</b> , 189, e9-e13	4.5 1
275	Targeting MCL-1 in hematologic malignancies: Rationale and progress. <i>Blood Reviews</i> , <b>2020</b> , 44, 100672	11.1 57
274	The CD33 splice isoform lacking exon 2 as therapeutic target in human acute myeloid leukemia. <i>Leukemia</i> , <b>2020</b> , 34, 2479-2483	10.7 6
273	Randomized phase 1 study of sequential ("primed") vs. concurrent decitabine in combination with cladribine, cytarabine, G-CSF, and mitoxantrone (CLAG-M) in adults with newly diagnosed or relapsed/refractory acute myeloid leukemia (AML) or other high-grade myeloid neoplasm. <i>Leukemia and Lymphoma</i> , <b>2020</b> , 61, 1728-1731	1.9 0
272	Impact of pretransplant measurable residual disease on the outcome of allogeneic hematopoietic cell transplantation in adult monosomal karyotype AML. <i>Leukemia</i> , <b>2020</b> , 34, 1577-1587	10.7 10
271	Selection of initial therapy for newly-diagnosed adult acute myeloid leukemia: Limitations of predictive models. <i>Blood Reviews</i> , <b>2020</b> , 44, 100679	11.1 12
270	Interaction of Remission Status and Cause of Death in Acute Myeloid Leukemia. <i>Blood</i> , <b>2020</b> , 136, 12-13	2.2
269	Practice patterns and outcomes for adults with acute myeloid leukemia receiving care in community vs academic settings. <i>Hematology American Society of Hematology Education Program</i> , <b>2020</b> , 2020, 129-134	3.1 5
268	Early achievement of measurable residual disease (MRD)-negative complete remission as predictor of outcome after myeloablative allogeneic hematopoietic cell transplantation in acute myeloid leukemia. <i>Bone Marrow Transplantation</i> , <b>2020</b> , 55, 669-672	4.4 4

267	Development and validation of the AML-QOL: a quality of life instrument for patients with acute myeloid leukemia. <i>Leukemia and Lymphoma</i> , <b>2020</b> , 61, 1158-1167	1.9	7
266	Need for routine examination of left ventricular ejection fraction in patients with AML. <i>Leukemia</i> , <b>2020</b> , 34, 1169-1171	10.7	1
265	Comparative analysis of total body irradiation (TBI)-based and non-TBI-based myeloablative conditioning for acute myeloid leukemia in remission with or without measurable residual disease. <i>Leukemia</i> , <b>2020</b> , 34, 1701-1705	10.7	3
264	Accuracy of SIE/SIES/GITMO Consensus Criteria for Unfitness to Predict Early Mortality After Intensive Chemotherapy in Adults With AML or Other High-Grade Myeloid Neoplasm. <i>Journal of Clinical Oncology</i> , <b>2020</b> , 38, 4163-4174	2.2	10
263	Association of Measurable Residual Disease With Survival Outcomes in Patients With Acute Myeloid Leukemia: A Systematic Review and Meta-analysis. <i>JAMA Oncology</i> , <b>2020</b> , 6, 1890-1899	13.4	57
262	Anti-apoptotic BCL-2 family proteins confer resistance to calicheamicin-based antibody-drug conjugate therapy of acute leukemia. <i>Leukemia and Lymphoma</i> , <b>2020</b> , 61, 2990-2994	1.9	2
261	Special considerations in the management of adult patients with acute leukaemias and myeloid neoplasms in the COVID-19 era: recommendations from a panel of international experts. <i>Lancet Haematology</i> , <b>2020</b> , 7, e601-e612	14.6	41
260	Conditioning Intensity, Pre-Transplant Flow Cytometric Measurable Residual Disease, and Outcome in Adults with Acute Myeloid Leukemia Undergoing Allogeneic Hematopoietic Cell Transplantation. <i>Cancers</i> , <b>2020</b> , 12,	6.6	12
259	Early hospital discharge after intensive induction chemotherapy for adults with acute myeloid leukemia or other high-grade myeloid neoplasm. <i>Leukemia</i> , <b>2020</b> , 34, 635-639	10.7	6
258	Outpatient intensive induction chemotherapy for acute myeloid leukemia and high-risk myelodysplastic syndrome. <i>Blood Advances</i> , <b>2020</b> , 4, 611-616	7.8	10
257	Independent Associations Between Glomerular Filtration Rate and Serum Bilirubin Level and Early Mortality in Acute Myeloid Leukemia. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , <b>2019</b> , 19, e633-e635	2	
256	In the Eye of the Beholder: A Conjunctival Lesion in a Woman With Acute Myelogenous Leukemia. <i>Clinical Infectious Diseases</i> , <b>2019</b> , 68, 525-529	11.6	
255	Novel monoclonal antibody-based therapies for acute myeloid leukemia. <i>Best Practice and Research in Clinical Haematology</i> , <b>2019</b> , 32, 116-126	4.2	10
254	Trends in Clinical Benefits and Costs of Novel Therapeutics in AML: at What Price Does Progress Come?. <i>Current Hematologic Malignancy Reports</i> , <b>2019</b> , 14, 171-178	4.4	11
253	Diagnostic utility of bronchoscopy in adults with acute myeloid leukemia and other high-grade myeloid neoplasms. <i>Leukemia and Lymphoma</i> , <b>2019</b> , 60, 2304-2307	1.9	2
252	Venetoclax Combined With Low-Dose Cytarabine for Previously Untreated Patients With Acute Myeloid Leukemia: Results From a Phase Ib/II Study. <i>Journal of Clinical Oncology</i> , <b>2019</b> , 37, 1277-1284	2.2	320
251	Outpatient induction and consolidation care strategies in acute myeloid leukemia. <i>Current Opinion in Hematology</i> , <b>2019</b> , 26, 65-70	3.3	10
250	Accrual Barriers and Detection of Early Toxicity Signal in Older Less-Fit Patients Treated with Azacitidine and Nivolumab for Newly Diagnosed Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS) in the SWOG 1612 Platform Randomized Phase II/III Clinical Trial. <i>Blood</i> , <b>2019</b> , 134, 3895-3895	2.2	5

249	Anti-Apoptotic BCL-2 Family Members Confer Resistance to Calicheamicin-Based Antibody-Drug Conjugate Therapy of Acute Leukemia. <i>Blood</i> , <b>2019</b> , 134, 2561-2561	2.2	
248	Pre-transplant bone marrow monocytic myeloid-derived suppressor cell frequency is not associated with outcome after allogeneic hematopoietic cell transplantation for acute myeloid leukemia in remission. <i>Bone Marrow Transplantation</i> , <b>2019</b> , 54, 1511-1514	4.4	1
247	COVA4231, a potent CD3/CD33 bispecific FynomAb with IgG-like pharmacokinetics for the treatment of acute myeloid leukemia. <i>Leukemia</i> , <b>2019</b> , 33, 805-808	10.7	8
246	Phase I/II trial of cladribine, high-dose cytarabine, mitoxantrone, and G-CSF with dose-escalated mitoxantrone for relapsed/refractory acute myeloid leukemia and other high-grade myeloid neoplasms. <i>Haematologica</i> , <b>2019</b> , 104, e143-e146	6.6	9
245	Prognostic and therapeutic role of CLEC12A in acute myeloid leukemia. <i>Blood Reviews</i> , <b>2019</b> , 34, 26-33	11.1	24
244	Second cycle remission achievement with 7+3 and survival in adults with newly diagnosed acute myeloid leukemia: analysis of recent SWOG trials. <i>Leukemia</i> , <b>2019</b> , 33, 554-558	10.7	6
243	Relationship between CD33 expression, splicing polymorphism, and cytotoxicity of gemtuzumab ozogamicin and the CD33/CD3 BiTE AMG 330. <i>Haematologica</i> , <b>2019</b> , 104, e59-e62	6.6	8
242	A comparison of patients with acute myeloid leukemia and high-risk myelodysplastic syndrome treated on versus off study. <i>Leukemia and Lymphoma</i> , <b>2019</b> , 60, 1023-1029	1.9	4
241	Engineering resistance to CD33-targeted immunotherapy in normal hematopoiesis by CRISPR/Cas9-deletion of CD33 exon 2. <i>Leukemia</i> , <b>2019</b> , 33, 762-808	10.7	24
240	Deep NPM1 Sequencing Following Allogeneic Hematopoietic Cell Transplantation Improves Risk Assessment in Adults with NPM1-Mutated AML. <i>Biology of Blood and Marrow Transplantation</i> , <b>2018</b> , 24, 1615-1620	4.7	20
239	Simultaneous multiple interaction T-cell engaging (SMITE) bispecific antibodies overcome bispecific T-cell engager (BiTE) resistance via CD28 co-stimulation. <i>Leukemia</i> , <b>2018</b> , 32, 1239-1243	10.7	38
238	Unsatisfactory efficacy in randomized study of reduced-dose CPX-351 for medically less fit adults with newly diagnosed acute myeloid leukemia or other high-grade myeloid neoplasm. <i>Haematologica</i> , <b>2018</b> , 103, e106-e109	6.6	18
237	Minimal/measurable residual disease in AML: a consensus document from the European LeukemiaNet MRD Working Party. <i>Blood</i> , <b>2018</b> , 131, 1275-1291	2.2	528
236	Phase 1/2 trial of GCLAM with dose-escalated mitoxantrone for newly diagnosed AML or other high-grade myeloid neoplasms. <i>Leukemia</i> , <b>2018</b> , 32, 2352-2362	10.7	21
235	Advancements in the management of medically less-fit and older adults with newly diagnosed acute myeloid leukemia. <i>Expert Opinion on Pharmacotherapy</i> , <b>2018</b> , 19, 865-882	4	11
234	Investigational CD33-targeted therapeutics for acute myeloid leukemia. <i>Expert Opinion on Investigational Drugs</i> , <b>2018</b> , 27, 339-348	5.9	49
233	Patient-reported outcomes in acute myeloid leukemia: Where are we now?. <i>Blood Reviews</i> , <b>2018</b> , 32, 81-87	11.1	28
232	Quality of life from the perspective of the patient with acute myeloid leukemia. <i>Cancer</i> , <b>2018</b> , 124, 145-152	11.1	19

231	A phase 1 trial of vadastuximab talirine combined with hypomethylating agents in patients with CD33-positive AML. <i>Blood</i> , <b>2018</b> , 132, 1125-1133	2.2	40
230	Impact of region of diagnosis, ethnicity, age, and gender on survival in acute myeloid leukemia (AML). <i>Journal of Drug Assessment</i> , <b>2018</b> , 7, 51-53	1.5	11
229	A Phase 1 First-in-Human Study of AMG 330, an Anti-CD33 Bispecific T-Cell Engager (BiTE <sup>®</sup> ) Antibody Construct, in Relapsed/Refractory Acute Myeloid Leukemia (R/R AML). <i>Blood</i> , <b>2018</b> , 132, 25-25	2.2	41
228	Use of Gemtuzumab Ozogamicin for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia (AML) or Acute Promyelocytic Leukemia (APL) in an Expanded Access Setting at Our Cancer Consortium. <i>Blood</i> , <b>2018</b> , 132, 2710-2710	2.2	1
227	Addition of Crenolanib to Induction Chemotherapy Overcomes the Poor Prognostic Impact of Co-Occurring Driver Mutations in Patients with Newly Diagnosed FLT3-Mutated AML. <i>Blood</i> , <b>2018</b> , 132, 1436-1436 <sup>9</sup>	2.2	9
226	Predicting Induction Toxicity with 7+3: Analysis of SWOG Trial S1203. <i>Blood</i> , <b>2018</b> , 132, 1403-1403	2.2	2
225	Venetoclax with Low-Dose Cytarabine Induces Rapid, Deep, and Durable Responses in Previously Untreated Older Adults with AML Ineligible for Intensive Chemotherapy. <i>Blood</i> , <b>2018</b> , 132, 284-284	2.2	26
224	Validation of the AML-QOL: A Quality of Life Instrument for Patients with Acute Myeloid Leukemia and Other Aggressive Myeloid Neoplasms. <i>Blood</i> , <b>2018</b> , 132, 4822-4822	2.2	
223	Pre-Transplant Monocytic Myeloid-Derived Suppressor Cell Frequency Has No Prognostic Role for Outcome after Allogeneic Hematopoietic Cell Transplantation for Acute Myeloid Leukemia in Remission. <i>Blood</i> , <b>2018</b> , 132, 5255-5255	2.2	
222	Engineering Resistance to CD33-Targeted Immunotherapy in Normal Hematopoiesis By CRISPR/Cas9-Deletion of CD33 Exon 2. <i>Blood</i> , <b>2018</b> , 132, 2200-2200	2.2	
221	2nd cycle Remission Achievement with 7+3 Is Associated with Shorter Survival in Adults with Newly Diagnosed Acute Myeloid Leukemia: Analysis of Recent SWOG Trials. <i>Blood</i> , <b>2018</b> , 132, 3978-3978	2.2	
220	A phase 1 trial of vadastuximab talirine as monotherapy in patients with CD33-positive acute myeloid leukemia. <i>Blood</i> , <b>2018</b> , 131, 387-396	2.2	95
219	Characterization of SGN-CD123A, A Potent CD123-Directed Antibody-Drug Conjugate for Acute Myeloid Leukemia. <i>Molecular Cancer Therapeutics</i> , <b>2018</b> , 17, 554-564	6.1	64
218	Evaluating measurable residual disease in acute myeloid leukemia. <i>Blood Advances</i> , <b>2018</b> , 2, 1356-1366	7.8	87
217	AML Debate: Use Gemtuzumab Ozogamicin in Most AML Patients vs. Use in CBF Patients or Not at All? Pro. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , <b>2018</b> , 18, S61-S63	2	
216	Next-generation sequencing for measuring minimal residual disease in AML. <i>Nature Reviews Clinical Oncology</i> , <b>2018</b> , 15, 473-474	19.4	4
215	Intergroup LEAP trial (S1612): A randomized phase 2/3 platform trial to test novel therapeutics in medically less fit older adults with acute myeloid leukemia. <i>American Journal of Hematology</i> , <b>2018</b> , 93, E49-E52	7.1	9
214	Minimal residual disease prior to allogeneic hematopoietic cell transplantation in acute myeloid leukemia: a meta-analysis. <i>Haematologica</i> , <b>2017</b> , 102, 865-873	6.6	132

213	Sinusoidal obstruction syndrome following CD33-targeted therapy in acute myeloid leukemia. <i>Blood</i> , <b>2017</b> , 129, 2330-2332	2.2	31
212	Mitoxantrone, etoposide and cytarabine following epigenetic priming with decitabine in adults with relapsed/refractory acute myeloid leukemia or other high-grade myeloid neoplasms: a phase 1/2 study. <i>Leukemia</i> , <b>2017</b> , 31, 2560-2567	10.7	22
211	Should patients with acute myeloid leukemia and measurable residual disease be transplanted in first complete remission?. <i>Current Opinion in Hematology</i> , <b>2017</b> , 24, 132-138	3.3	9
210	Gemtuzumab ozogamicin in acute myeloid leukemia. <i>Leukemia</i> , <b>2017</b> , 31, 1855-1868	10.7	128
209	Measurable residual disease testing in acute myeloid leukaemia. <i>Leukemia</i> , <b>2017</b> , 31, 1482-1490	10.7	132
208	Flow cytometric demonstration of decrease in bone marrow leukemic blasts after Day 14 without further therapy in acute myeloid leukemia. <i>Leukemia and Lymphoma</i> , <b>2017</b> , 58, 2717-2719	1.9	7
207	Characteristics and outcome of patients with therapy-related acute promyelocytic leukemia front-line treated with or without arsenic trioxide. <i>Leukemia</i> , <b>2017</b> , 31, 2347-2354	10.7	28
206	Patients treated for acute VTE during periods of treatment-related thrombocytopenia have high rates of recurrent thrombosis and transfusion-related adverse outcomes. <i>Journal of Thrombosis and Thrombolysis</i> , <b>2017</b> , 44, 442-447	5.1	22
205	The Prognostic Significance of Measurable ("Minimal") Residual Disease in Acute Myeloid Leukemia. <i>Current Hematologic Malignancy Reports</i> , <b>2017</b> , 12, 547-556	4.4	14
204	CD33 Splicing Polymorphism Determines Gemtuzumab Ozogamicin Response in De Novo Acute Myeloid Leukemia: Report From Randomized Phase III Children's Oncology Group Trial AAML0531. <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, 2674-2682	2.2	93
203	Is there a need for morphologic exam to detect relapse in AML if multi-parameter flow cytometry is employed?. <i>Leukemia</i> , <b>2017</b> , 31, 2536-2537	10.7	10
202	Association of Risk Factors, Mortality, and Care Costs of Adults With Acute Myeloid Leukemia With Admission to the Intensive Care Unit. <i>JAMA Oncology</i> , <b>2017</b> , 3, 374-381	13.4	42
201	Phase 1/2 Study of Venetoclax with Low-Dose Cytarabine in Treatment-Naive, Elderly Patients with Acute Myeloid Leukemia Unfit for Intensive Chemotherapy: 1-Year Outcomes. <i>Blood</i> , <b>2017</b> , 130, 890-890	2.2	39
200	Effect of cytarabine/anthracycline/crenolanib induction on minimal residual disease (MRD) in newly diagnosed FLT3 mutant AML. <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, 7016-7016	2.2	3
199	Determinants of quality of life in patients with acute myeloid leukemia. <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, e18528-e18528	2.2	2
198	Comparative analysis of flow cytometry and morphology for the detection of acute myeloid leukaemia cells in cerebrospinal fluid. <i>British Journal of Haematology</i> , <b>2016</b> , 172, 134-6	4.5	5
197	Phase II study of tosedostat with cytarabine or decitabine in newly diagnosed older patients with acute myeloid leukaemia or high-risk MDS. <i>British Journal of Haematology</i> , <b>2016</b> , 172, 238-45	4.5	22
196	SGN-CD33A (Vadastuximab Talirine) followed by Allogeneic Hematopoietic Stem Cell Transplant (AlloHSCT) Results in Durable Complete Remissions (CRs) in Patients with Acute Myeloid Leukemia (AML). <i>Biology of Blood and Marrow Transplantation</i> , <b>2016</b> , 22, S211-S212	4.7	4

195	Incorporating measurable (minimal) residual disease-directed treatment strategies to optimize outcomes in adults with acute myeloid leukemia. <i>Leukemia and Lymphoma</i> , <b>2016</b> , 57, 1527-33	1.9	6
194	Activity of the oral mitogen-activated protein kinase kinase inhibitor trametinib in RAS-mutant relapsed or refractory myeloid malignancies. <i>Cancer</i> , <b>2016</b> , 122, 1871-9	6.4	86
193	Antigen-specific immunotherapy for acute myeloid leukemia: where are we now, and where do we go from here?. <i>Expert Review of Hematology</i> , <b>2016</b> , 9, 335-50	2.8	19
192	Prediction of early death in adults with relapsed or refractory acute myeloid leukemia. <i>Leukemia and Lymphoma</i> , <b>2016</b> , 57, 2421-4	1.9	6
191	Allogeneic Hematopoietic Cell Transplantation for Acute Myeloid Leukemia: Time to Move Toward a Minimal Residual Disease-Based Definition of Complete Remission?. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, 329-36	2.2	270
190	Pre- and post-transplant quantification of measurable (minimal) residual disease via multiparameter flow cytometry in adult acute myeloid leukemia. <i>Leukemia</i> , <b>2016</b> , 30, 1456-64	10.7	107
189	Safety and Efficacy of Venetoclax Plus Low-Dose Cytarabine in Treatment-Naive Patients Aged $\geq 5$ Years with Acute Myeloid Leukemia. <i>Blood</i> , <b>2016</b> , 128, 102-102	2.2	39
188	A Phase 1/2 Study of G-CSF, Cladribine, Cytarabine, and Dose-Escalated Mitoxantrone (G-CLAM) in Adults with Newly Diagnosed Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS). <i>Blood</i> , <b>2016</b> , 128, 1068-1068	2.2	1
187	Crenolanib, a Type I FLT3 TKI, Can be Safely Combined with Cytarabine and Anthracycline Induction Chemotherapy and Results in High Response Rates in Patients with Newly Diagnosed FLT3 Mutant Acute Myeloid Leukemia (AML). <i>Blood</i> , <b>2016</b> , 128, 1071-1071	2.2	36
186	A Phase 1b Study of Vadastuximab Talirine in Combination with 7+3 Induction Therapy for Patients with Newly Diagnosed Acute Myeloid Leukemia (AML). <i>Blood</i> , <b>2016</b> , 128, 211-211	2.2	21
185	Results from Ongoing Phase 2 Trial of SL-401 As Consolidation Therapy in Patients with Acute Myeloid Leukemia (AML) in Remission with High Relapse Risk Including Minimal Residual Disease (MRD). <i>Blood</i> , <b>2016</b> , 128, 215-215	2.2	18
184	A Phase 1b Study of Vadastuximab Talirine As Maintenance and in Combination with Standard Consolidation for Patients with Acute Myeloid Leukemia (AML). <i>Blood</i> , <b>2016</b> , 128, 340-340	2.2	4
183	Vadastuximab Talirine Monotherapy in Older Patients with Treatment Naive CD33-Positive Acute Myeloid Leukemia (AML). <i>Blood</i> , <b>2016</b> , 128, 590-590	2.2	18
182	Vadastuximab Talirine Plus Hypomethylating Agents: A Well-Tolerated Regimen with High Remission Rate in Frontline Older Patients with Acute Myeloid Leukemia (AML). <i>Blood</i> , <b>2016</b> , 128, 591-591 <sup>2</sup>	3.0	30
181	Phase 1b/2 study of venetoclax with low-dose cytarabine in treatment-naive patients age $\geq 5$ with acute myelogenous leukemia.. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, 7007-7007	2.2	19
180	A phase 1, open-label, dose-escalation, multicenter study to evaluate the tolerability, safety, pharmacokinetics, and activity of ADCT-301 in patients with relapsed or refractory CD25-positive acute myeloid leukemia.. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, TPS7071-TPS7071	2.2	2
179	Expression and functional characterization of CD33 transcript variants in human acute myeloid leukemia. <i>Oncotarget</i> , <b>2016</b> , 7, 43281-43294	3.3	31
178	Prognostic implication of minimal residual disease in AML.. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, 7016-7016	2.2	16



177	The Role of Notch in Vascular Endothelial Cell-Mediated Protection of AML Precursors from Targeted Therapy. <i>Blood</i> , <b>2016</b> , 128, 2750-2750	2.2	
176	Decitabine Plus Cytarabine for Induction of Remission in Newly Diagnosed Elderly AML or High Risk MDS Patients. <i>Blood</i> , <b>2016</b> , 128, 5207-5207	2.2	
175	CD33 Splicing Polymorphism Is a Strong Predictor of Therapeutic Efficacy of Gemtuzumab Ozogamicin in De Novo AML: Report from COG-AAML0531 Study. <i>Blood</i> , <b>2016</b> , 128, 2743-2743	2.2	
174	Rates of CR with and without Measurable Residual Disease after Induction Treatment with "7+3" or Azacitidine/Decitabine for Newly-Diagnosed AML. <i>Blood</i> , <b>2016</b> , 128, 2792-2792	2.2	
173	The Effect of Measurable Residual Disease at the Time of Allogeneic Hematopoietic Cell Transplantation on Outcomes in Patients with Acute Myeloid Leukemia: A Meta-Analysis. <i>Blood</i> , <b>2016</b> , 128, 2842-2842	2.2	
172	A Precision Medicine Approach Incorporating Both Molecular and In Vitro Functional Data to Treat Patients with Relapsed/Refractory Acute Myeloid Leukemia. <i>Blood</i> , <b>2016</b> , 128, 4043-4043	2.2	
171	Mitoxantrone, Etoposide, and Cytarabine (MEC) Following Epigenetic Priming with Decitabine in Adults with Relapsed/Refractory Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS): Final Results from a Phase 1/2 Study. <i>Blood</i> , <b>2016</b> , 128, 1064-1064	2.2	
170	Should acute myeloid leukemia patients with actionable targets be offered investigational treatment after failing one cycle of standard induction therapy?. <i>Current Opinion in Hematology</i> , <b>2016</b> , 23, 102-7	3.3	2
169	Reply to C.S. Hourigan et al. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, 2558-9	2.2	1
168	Characterization of CD33/CD3 Tetravalent Bispecific Tandem Diabodies (TandAbs) for the Treatment of Acute Myeloid Leukemia. <i>Clinical Cancer Research</i> , <b>2016</b> , 22, 5829-5838	12.9	62
167	T-Cell Receptor-Engineered Cells for the Treatment of Hematologic Malignancies. <i>Current Hematologic Malignancy Reports</i> , <b>2016</b> , 11, 311-7	4.4	5
166	Does outcome of second salvage therapy in relapsed or refractory acute myeloid leukemia depend on intensity of either first or second salvage therapy?. <i>Leukemia and Lymphoma</i> , <b>2016</b> , 57, 1205-7	1.9	1
165	Effect of measurable (Minimal) residual disease (MRD) information on prediction of relapse and survival in adult acute myeloid leukemia. <i>Leukemia</i> , <b>2016</b> , 30, 2080-2083	10.7	45
164	Outpatient care of patients with acute myeloid leukemia: Benefits, barriers, and future considerations. <i>Leukemia Research</i> , <b>2016</b> , 45, 53-8	2.7	30
163	Maintenance therapy in acute myeloid leukemia: an evidence-based review of randomized trials. <i>Blood</i> , <b>2016</b> , 128, 763-73	2.2	37
162	Correlation between peripheral blood and bone marrow regarding FLT3-ITD and NPM1 mutational status in patients with acute myeloid leukemia. <i>Haematologica</i> , <b>2015</b> , 100, e97-8	6.6	8
161	Update on antigen-specific immunotherapy of acute myeloid leukemia. <i>Current Hematologic Malignancy Reports</i> , <b>2015</b> , 10, 65-75	4.4	12
160	Effect of genetic profiling on prediction of therapeutic resistance and survival in adult acute myeloid leukemia. <i>Leukemia</i> , <b>2015</b> , 29, 2104-7	10.7	41

159	Relation of clinical response and minimal residual disease and their prognostic impact on outcome in acute myeloid leukemia. <i>Journal of Clinical Oncology</i> , <b>2015</b> , 33, 1258-64	2.2	163
158	Multimerin-1 (MMRN1) as Novel Adverse Marker in Pediatric Acute Myeloid Leukemia: A Report from the Children's Oncology Group. <i>Clinical Cancer Research</i> , <b>2015</b> , 21, 3187-95	12.9	9
157	Effect of allogeneic hematopoietic cell transplantation in first complete remission on post-relapse complete remission rate and survival in acute myeloid leukemia. <i>Haematologica</i> , <b>2015</b> , 100, e254-6	6.6	3
156	T-cell ligands modulate the cytolytic activity of the CD33/CD3 BiTE antibody construct, AMG 330. <i>Blood Cancer Journal</i> , <b>2015</b> , 5, e340	7	44
155	Resource Utilization and Safety of Outpatient Management Following Intensive Induction or Salvage Chemotherapy for Acute Myeloid Leukemia or Myelodysplastic Syndrome: A Nonrandomized Clinical Comparative Analysis. <i>JAMA Oncology</i> , <b>2015</b> , 1, 1120-7	13.4	33
154	How Do Pretransplantation Peripheral Blood Counts Inform Us about Post-Transplantation Outcomes in Acute Myeloid Leukemia?. <i>Biology of Blood and Marrow Transplantation</i> , <b>2015</b> , 21, 1340-2	4.7	
153	The treatment-related mortality score is associated with non-fatal adverse events following intensive AML induction chemotherapy. <i>Blood Cancer Journal</i> , <b>2015</b> , 5, e276	7	12
152	Fate of patients with newly diagnosed acute myeloid leukemia who fail primary induction therapy. <i>Biology of Blood and Marrow Transplantation</i> , <b>2015</b> , 21, 559-64	4.7	42
151	Management of older or unfit patients with acute myeloid leukemia. <i>Leukemia</i> , <b>2015</b> , 29, 770-5	10.7	72
150	Resistance prediction in AML: analysis of 4601 patients from MRC/NCRI, HOVON/SAKK, SWOG and MD Anderson Cancer Center. <i>Leukemia</i> , <b>2015</b> , 29, 312-20	10.7	106
149	Factors associated with early reinduction chemotherapy for adults with acute myeloid leukemia. <i>Leukemia and Lymphoma</i> , <b>2015</b> , 56, 782-4	1.9	3
148	Antibody-Based Therapeutics Targeting CD33, CD45, and CD66 <b>2015</b> , 531-555		4
147	Comparison of minimal residual disease as outcome predictor for AML patients in first complete remission undergoing myeloablative or nonmyeloablative allogeneic hematopoietic cell transplantation. <i>Leukemia</i> , <b>2015</b> , 29, 137-44	10.7	142
146	High expression of myocyte enhancer factor 2C (MEF2C) is associated with adverse-risk features and poor outcome in pediatric acute myeloid leukemia: a report from the Children's Oncology Group. <i>Journal of Hematology and Oncology</i> , <b>2015</b> , 8, 115	22.4	28
145	Antigen-specific immunotherapies for acute myeloid leukemia. <i>Hematology American Society of Hematology Education Program</i> , <b>2015</b> , 2015, 584-95	3.1	19
144	Minimal residual disease-directed therapy in acute myeloid leukemia. <i>Blood</i> , <b>2015</b> , 125, 2331-5	2.2	33
143	Primary antifungal prophylaxis during curative-intent therapy for acute myeloid leukemia. <i>Blood</i> , <b>2015</b> , 126, 2790-7	2.2	37
142	Empiric definition of eligibility criteria for clinical trials in relapsed/refractory acute myeloid leukemia: analysis of 1,892 patients from HOVON/SAKK and SWOG. <i>Haematologica</i> , <b>2015</b> , 100, e409-11	6.6	9

141	A phase I/II study of oral clofarabine plus low-dose cytarabine in previously treated acute myeloid leukaemia and high-risk myelodysplastic syndrome patients at least 60 years of age. <i>British Journal of Haematology</i> , <b>2015</b> , 170, 349-55	4.5	7
140	The Broad Anti-AML Activity of the CD33/CD3 BiTE Antibody Construct, AMG 330, Is Impacted by Disease Stage and Risk. <i>PLoS ONE</i> , <b>2015</b> , 10, e0135945	3.7	35
139	Minimal residual disease in acute myeloid leukemia--current status and future perspectives. <i>Current Hematologic Malignancy Reports</i> , <b>2015</b> , 10, 132-44	4.4	24
138	G-CSF priming, clofarabine, and high dose cytarabine (GCLAC) for upfront treatment of acute myeloid leukemia, advanced myelodysplastic syndrome or advanced myeloproliferative neoplasm. <i>American Journal of Hematology</i> , <b>2015</b> , 90, 295-300	7.1	15
137	Low platelet count reduces subsequent complete remission rate despite marrow with . <i>Leukemia</i> , <b>2015</b> , 29, 1779-80	10.7	5
136	Number of courses of induction therapy independently predicts outcome after allogeneic transplantation for acute myeloid leukemia in first morphological remission. <i>Biology of Blood and Marrow Transplantation</i> , <b>2015</b> , 21, 373-8	4.7	17
135	Effect of Minimal Residual Disease (MRD) Information on Prediction of Relapse and Survival in Adult Acute Myeloid Leukemia. <i>Blood</i> , <b>2015</b> , 126, 2569-2569	2.2	1
134	A Phase 1 Trial of SGN-CD33A As Monotherapy in Patients with CD33-Positive Acute Myeloid Leukemia (AML). <i>Blood</i> , <b>2015</b> , 126, 324-324	2.2	25
133	SGN-CD123A, a Pyrrolobenzodiazepine Dimer Linked Anti-CD123 Antibody Drug Conjugate, Demonstrates Effective Anti-Leukemic Activity in Multiple Preclinical Models of AML. <i>Blood</i> , <b>2015</b> , 126, 330-330	2.2	14
132	Minimal Residual Disease (MRD) As Exploratory Endpoint in a Phase 1 Study of the Anti-CD123 Mab CSL362 Given As Post-Remission Therapy in Adult Acute Myeloid Leukemia (AML). <i>Blood</i> , <b>2015</b> , 126, 3819-3819	2.2	7
131	SGN-CD33A Plus Hypomethylating Agents: A Novel, Well-Tolerated Regimen with High Remission Rate in Frontline Unfit AML. <i>Blood</i> , <b>2015</b> , 126, 454-454	2.2	15
130	Construction and characterization of novel CD33/CD3 tandem diabodies (TandAbs) for the treatment of acute myeloid leukemia (AML).. <i>Journal of Clinical Oncology</i> , <b>2015</b> , 33, 7067-7067	2.2	2
129	Cell Signaling and Resistance to Immunotoxins. <i>Resistance To Targeted Anti-cancer Therapeutics</i> , <b>2015</b> , 75-87	0.3	
128	Discrepancy in bone marrow blast counts between morphology and flow cytometry and its potential clinical implications.. <i>Journal of Clinical Oncology</i> , <b>2015</b> , 33, e18031-e18031	2.2	
127	Allogeneic Hematopoietic Cell Transplantation for Acute Myeloid Leukemia: Is It Time to Move Toward a Minimal Residual Disease-Based Definition of Complete Remission?. <i>Blood</i> , <b>2015</b> , 126, 2571-2571	2.2	1
126	High Expression of Myocyte Enhancer Factor 2C (MEF2C) Is Associated with Adverse Risk Features and Poor Outcome in Pediatric Acute Myeloid Leukemia: A Report from the Children's Oncology Group. <i>Blood</i> , <b>2015</b> , 126, 2570-2570	2.2	
125	Oncology Providers Ability to Prognosticate Patient Outcomes: An Analysis of the Survey on Provider Assessment of Risk (SPAR) Study. <i>Blood</i> , <b>2015</b> , 126, 5635-5635	2.2	
124	Significance of Peri-Transplant Dynamics of Minimal Residual Disease (MRD) in Adults with Acute Myeloid Leukemia (AML) in Morphological Remission Undergoing Myeloablative Allogeneic Hematopoietic Cell Transplantation. <i>Blood</i> , <b>2015</b> , 126, 173-173	2.2	

123	Phase 1 Trial of G-CSF, Cladribine, Cytarabine, and Dose-Escalated Mitoxantrone (G-CLAM) in Adults with Relapsed/Refractory Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndromes (MDS). <i>Blood</i> , <b>2015</b> , 126, 1339-1339	2.2	
122	Chronic myeloid leukemia in lymphoid blast crisis. <i>European Journal of Haematology</i> , <b>2014</b> , 92, 458	3.8	
121	Rapid rate of peripheral blood blast clearance accurately predicts complete remission in acute myeloid leukemia. <i>Leukemia</i> , <b>2014</b> , 28, 713-6	10.7	25
120	Cellular determinants for preclinical activity of a novel CD33/CD3 bispecific T-cell engager (BiTE) antibody, AMG 330, against human AML. <i>Blood</i> , <b>2014</b> , 123, 554-61	2.2	132
119	Outpatient bendamustine and idarubicin for upfront therapy of elderly acute myeloid leukaemia/myelodysplastic syndrome: a phase I/II study using an innovative statistical design. <i>British Journal of Haematology</i> , <b>2014</b> , 166, 375-81	4.5	1
118	Heterogeneity of clonal expansion and maturation-linked mutation acquisition in hematopoietic progenitors in human acute myeloid leukemia. <i>Leukemia</i> , <b>2014</b> , 28, 1969-77	10.7	9
117	Prediction of adverse events during intensive induction chemotherapy for acute myeloid leukemia or high-grade myelodysplastic syndromes. <i>American Journal of Hematology</i> , <b>2014</b> , 89, 423-8	7.1	36
116	Mcl-1 dependence predicts response to vorinostat and gemtuzumab ozogamicin in acute myeloid leukemia. <i>Leukemia Research</i> , <b>2014</b> , 38, 564-8	2.7	10
115	Gemtuzumab ozogamicin in combination with vorinostat and azacitidine in older patients with relapsed or refractory acute myeloid leukemia: a phase I/II study. <i>Haematologica</i> , <b>2014</b> , 99, 54-9	6.6	39
114	Outcome of patients with abn1(17p) acute myeloid leukemia after allogeneic hematopoietic stem cell transplantation. <i>Blood</i> , <b>2014</b> , 123, 2960-7	2.2	51
113	Preclinical and early clinical evaluation of the oral AKT inhibitor, MK-2206, for the treatment of acute myelogenous leukemia. <i>Clinical Cancer Research</i> , <b>2014</b> , 20, 2226-35	12.9	56
112	Non-steroidal anti-inflammatory drugs and cancer risk in women: results from the Women's Health Initiative. <i>International Journal of Cancer</i> , <b>2014</b> , 135, 1869-83	7.5	44
111	High expression of suppressor of cytokine signaling-2 predicts poor outcome in pediatric acute myeloid leukemia: a report from the Children's Oncology Group. <i>Leukemia and Lymphoma</i> , <b>2014</b> , 55, 2817-21	1.9	14
110	The past and future of CD33 as therapeutic target in acute myeloid leukemia. <i>Blood Reviews</i> , <b>2014</b> , 28, 143-53	11.1	107
109	Four different regimens of farnesyltransferase inhibitor tipifarnib in older, untreated acute myeloid leukemia patients: North American Intergroup Phase II study SWOG S0432. <i>Leukemia Research</i> , <b>2014</b> , 38, 329-33	2.7	20
108	First-in Man, Phase 1 Study of CSL362 (Anti-IL3R $\gamma$ Anti-CD123 Monoclonal Antibody) in Patients with CD123+ Acute Myeloid Leukemia (AML) in CR at High Risk for Early Relapse. <i>Blood</i> , <b>2014</b> , 124, 120-120	2.2	40
107	The Broad Activity of the CD33/CD3 Bispecific BiTE Antibody AMG 330 in Primary Human AML Is Impacted By Disease Stage and Cytogenetic/Molecular Risk. <i>Blood</i> , <b>2014</b> , 124, 266-266	2.2	1
106	Idarubicin, Cytarabine and Pravastatin As Induction Therapy for Untreated Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndrome. <i>Blood</i> , <b>2014</b> , 124, 3732-3732	2.2	1

105	Interim Analysis of a Phase 1 Trial of SGN-CD33A in Patients with CD33-Positive Acute Myeloid Leukemia (AML). <i>Blood</i> , <b>2014</b> , 124, 623-623	2.2	24
104	Randomized Study of Liposomal Cytarabine and Daunorubicin (CPX-351) for Adults with Untreated High-Risk Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML) at High Risk of Treatment-Related Mortality. <i>Blood</i> , <b>2014</b> , 124, 994-994	2.2	1
103	Correlation between peripheral blood and bone marrow regarding FLT3 ITD and NPM1 mutational status in patients with AML.. <i>Journal of Clinical Oncology</i> , <b>2014</b> , 32, 7077-7077	2.2	
102	A Randomized Phase II Study of Tosedostat in Combination with Either Cytarabine or Decitabine in Newly Diagnosed Older Patients with Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome. <i>Blood</i> , <b>2014</b> , 124, 3690-3690	2.2	
101	Mitoxantrone, Etoposide, and Cytarabine (MEC) Following Epigenetic Priming with Decitabine in Adults with Relapsed/Refractory Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS): A Phase 1 Study. <i>Blood</i> , <b>2014</b> , 124, 3730-3730	2.2	
100	Effect of Allogeneic Hematopoietic Cell Transplant in First Complete Remission on Post-Relapse CR Rate and Survival in Acute Myeloid Leukemia. <i>Blood</i> , <b>2014</b> , 124, 5257-5257	2.2	
99	Prediction of Treatment-Related Mortality in Patients with Relapsed and Refractory Acute Myeloid Leukemia. <i>Blood</i> , <b>2014</b> , 124, 2277-2277	2.2	
98	Empiric Definition of Eligibility Criteria for Clinical Trials in Relapsed/Refractory AML: Analysis of 1,892 Patients from HOVON/SAKK and SWOG. <i>Blood</i> , <b>2014</b> , 124, 3676-3676	2.2	
97	The Treatment Related Mortality Score Predicts Early Adverse Events during Intensive Induction Chemotherapy for Acute Myeloid Leukemia (AML). <i>Blood</i> , <b>2014</b> , 124, 2276-2276	2.2	
96	Prognostic and therapeutic implications of minimal residual disease at the time of transplantation in acute leukemia. <i>Bone Marrow Transplantation</i> , <b>2013</b> , 48, 630-41	4.4	74
95	Significance of expression of ITGA5 and its splice variants in acute myeloid leukemia: a report from the Children's Oncology Group. <i>American Journal of Hematology</i> , <b>2013</b> , 88, 694-702	7.1	6
94	Frequency of allogeneic hematopoietic cell transplantation among patients with high- or intermediate-risk acute myeloid leukemia in first complete remission. <i>Journal of Clinical Oncology</i> , <b>2013</b> , 31, 3883-8	2.2	35
93	Regular recreational physical activity and risk of hematologic malignancies: results from the prospective VITamins And lifestyle (VITAL) study. <i>Annals of Oncology</i> , <b>2013</b> , 24, 1370-7	10.3	12
92	High expression of neutrophil elastase predicts improved survival in pediatric acute myeloid leukemia: a report from the Children's Oncology Group. <i>Leukemia and Lymphoma</i> , <b>2013</b> , 54, 202-4	1.9	4
91	Significance of FAB subclassification of "acute myeloid leukemia, NOS" in the 2008 WHO classification: analysis of 5848 newly diagnosed patients. <i>Blood</i> , <b>2013</b> , 121, 2424-31	2.2	75
90	Mott cells. <i>European Journal of Haematology</i> , <b>2013</b> , 90, 83	3.8	3
89	Cyclosporine modulation of multidrug resistance in combination with pravastatin, mitoxantrone and etoposide for adult patients with relapsed/refractory acute myeloid leukemia: a phase 1/2 study. <i>Leukemia and Lymphoma</i> , <b>2013</b> , 54, 2534-6	1.9	10
88	Height as an explanatory factor for sex differences in human cancer. <i>Journal of the National Cancer Institute</i> , <b>2013</b> , 105, 860-8	9.7	45

87	Clinical significance of CD33 nonsynonymous single-nucleotide polymorphisms in pediatric patients with acute myeloid leukemia treated with gemtuzumab-ozogamicin-containing chemotherapy. <i>Clinical Cancer Research</i> , <b>2013</b> , 19, 1620-7	12.9	41
86	A model for prediction of FLT3-ITD and NPM1 (without FLT3-ITD) positivity in patients with newly diagnosed acute myeloid leukaemia. <i>British Journal of Haematology</i> , <b>2013</b> , 163, 130-2	4.5	
85	Associations between allergies and risk of hematologic malignancies: results from the VITamins and lifestyle cohort study. <i>American Journal of Hematology</i> , <b>2013</b> , 88, 1050-4	7.1	13
84	A phase 3 study of gemtuzumab ozogamicin during induction and postconsolidation therapy in younger patients with acute myeloid leukemia. <i>Blood</i> , <b>2013</b> , 121, 4854-60	2.2	441
83	CMV reactivation after allogeneic HCT and relapse risk: evidence for early protection in acute myeloid leukemia. <i>Blood</i> , <b>2013</b> , 122, 1316-24	2.2	218
82	SGN-CD33A: a novel CD33-targeting antibody-drug conjugate using a pyrrolobenzodiazepine dimer is active in models of drug-resistant AML. <i>Blood</i> , <b>2013</b> , 122, 1455-63	2.2	313
81	Significance of minimal residual disease before myeloablative allogeneic hematopoietic cell transplantation for AML in first and second complete remission. <i>Blood</i> , <b>2013</b> , 122, 1813-21	2.2	264
80	AKT signaling as a novel factor associated with in vitro resistance of human AML to gemtuzumab ozogamicin. <i>PLoS ONE</i> , <b>2013</b> , 8, e53518	3.7	30
79	Antibody-based therapy of acute myeloid leukemia with gemtuzumab ozogamicin. <i>Frontiers in Bioscience - Landmark</i> , <b>2013</b> , 18, 1311-34	2.8	46
78	Gemtuzumab Ozogamicin In Combination With Vorinostat and Azacitidine In Older Patients With Relapsed Or Refractory Acute Myeloid Leukemia (AML): Final Results From A Phase 1/2 Study. <i>Blood</i> , <b>2013</b> , 122, 3936-3936	2.2	2
77	Outpatient management following intensive induction or salvage chemotherapy for acute myeloid leukemia. <i>Clinical Advances in Hematology and Oncology</i> , <b>2013</b> , 11, 571-7	0.6	27
76	Outcome Of Patients With Abnl(17p) Acute Myeloid Leukemia After Allogeneic Hematopoietic Stem Cell Transplantation. <i>Blood</i> , <b>2013</b> , 122, 303-303	2.2	
75	Phase 2 Study Of Early Discharge and Outpatient Management Of Adult Patients Following Intensive Induction Chemotherapy For MDS and Non-APL AML. <i>Blood</i> , <b>2013</b> , 122, 2932-2932	2.2	
74	Novel Long-Term Co-Culture Approach Identifies Prognostically Important Heterogeneity Of Stem/Progenitor Cell Involvement In Human Acute Myeloid Leukemia. <i>Blood</i> , <b>2013</b> , 122, 1318-1318	2.2	
73	Acute myeloid leukemia stem cells and CD33-targeted immunotherapy. <i>Blood</i> , <b>2012</b> , 119, 6198-208	2.2	217
72	Correlation of CD33 expression level with disease characteristics and response to gemtuzumab ozogamicin containing chemotherapy in childhood AML. <i>Blood</i> , <b>2012</b> , 119, 3705-11	2.2	75
71	Myeloid sarcoma of the heart. <i>Leukemia and Lymphoma</i> , <b>2012</b> , 53, 2511-4	1.9	7
70	Phase II trial of vorinostat and gemtuzumab ozogamicin as induction and post-remission therapy in older adults with previously untreated acute myeloid leukemia. <i>Haematologica</i> , <b>2012</b> , 97, 739-42	6.6	24

69	Reply to F. Ferrara. <i>Journal of Clinical Oncology</i> , <b>2012</b> , 30, 463-464	2.2	0
68	SGN-CD33A: A Novel CD33-Directed Antibody-Drug Conjugate, Utilizing Pyrrolbenzodiazepine Dimers, Demonstrates Preclinical Antitumor Activity Against Multi-Drug Resistant Human AML. <i>Blood</i> , <b>2012</b> , 120, 3589-3589	2.2	5
67	Outpatient management following intensive induction chemotherapy for myelodysplastic syndromes and acute myeloid leukemia: a pilot study. <i>Haematologica</i> , <b>2011</b> , 96, 914-7	6.6	27
66	Cancer risk associated with long-term use of acetaminophen in the prospective VITamins and lifestyle (VITAL) study. <i>Cancer Epidemiology Biomarkers and Prevention</i> , <b>2011</b> , 20, 2637-41	4	10
65	Long-term use of acetaminophen, aspirin, and other nonsteroidal anti-inflammatory drugs and risk of hematologic malignancies: results from the prospective Vitamins and Lifestyle (VITAL) study. <i>Journal of Clinical Oncology</i> , <b>2011</b> , 29, 2424-31	2.2	41
64	Vitamin, mineral, and specialty supplements and risk of hematologic malignancies in the prospective VITamins And Lifestyle (VITAL) study. <i>Cancer Epidemiology Biomarkers and Prevention</i> , <b>2011</b> , 20, 2298-308	4	23
63	Impact of pretransplantation minimal residual disease, as detected by multiparametric flow cytometry, on outcome of myeloablative hematopoietic cell transplantation for acute myeloid leukemia. <i>Journal of Clinical Oncology</i> , <b>2011</b> , 29, 1190-7	2.2	270
62	Prediction of early death after induction therapy for newly diagnosed acute myeloid leukemia with pretreatment risk scores: a novel paradigm for treatment assignment. <i>Journal of Clinical Oncology</i> , <b>2011</b> , 29, 4417-23	2.2	230
61	Phase I/II trial of the MEK1/2 inhibitor GSK1120212 (GSK212) in patients (pts) with relapsed/refractory myeloid malignancies: Evidence of activity in pts with RAS mutation.. <i>Journal of Clinical Oncology</i> , <b>2011</b> , 29, 6506-6506	2.2	10
60	Targeted drug delivery by gemtuzumab ozogamicin: mechanism-based mathematical model for treatment strategy improvement and therapy individualization. <i>PLoS ONE</i> , <b>2011</b> , 6, e24265	3.7	25
59	Acute Myeloid Leukemia <b>2011</b> , 2, 219-237		2
58	Prognostic Import of French-American-British (FAB) System As Embedded in 2008 Revision of World Health Organization Classification of AML: Review of SWOG Data. <i>Blood</i> , <b>2011</b> , 118, 1446-1446	2.2	
57	Comparison of matched unrelated and matched related donor myeloablative hematopoietic cell transplantation for adults with acute myeloid leukemia in first remission. <i>Leukemia</i> , <b>2010</b> , 24, 1276-82	10.7	81
56	Effect of complete remission and responses less than complete remission on survival in acute myeloid leukemia: a combined Eastern Cooperative Oncology Group, Southwest Oncology Group, and M. D. Anderson Cancer Center Study. <i>Journal of Clinical Oncology</i> , <b>2010</b> , 28, 1766-71	2.2	145
55	High expression of the very late antigen-4 integrin independently predicts reduced risk of relapse and improved outcome in pediatric acute myeloid leukemia: a report from the children@ oncology group. <i>Journal of Clinical Oncology</i> , <b>2010</b> , 28, 2831-8	2.2	31
54	Pretargeted radioimmunotherapy for hematologic and other malignancies. <i>Cancer Biotherapy and Radiopharmaceuticals</i> , <b>2010</b> , 25, 125-42	3.9	27
53	Shortcomings in the clinical evaluation of new drugs: acute myeloid leukemia as paradigm. <i>Blood</i> , <b>2010</b> , 116, 2420-8	2.2	62
52	Quantitative Effect of Age In Predicting Empirically-Defined Treatment-Related Mortality and Resistance In Newly Diagnosed AML: Case Against Age Alone as Primary Determinant of Treatment Assignment. <i>Blood</i> , <b>2010</b> , 116, 2191-2191	2.2	8

51	Evaluation of Early Discharge After Hospital Treatment of Neutropenic Fever In Acute Myelogenous Leukemia (AML).. <i>Blood</i> , <b>2010</b> , 116, 3806-3806	2.2	
50	The power of comparative studies. <i>Leukemia Research</i> , <b>2009</b> , 33, 610-2	2.7	4
49	Association between plasma thiols and immune activation marker neopterin in stable coronary heart disease. <i>Clinical Chemistry and Laboratory Medicine</i> , <b>2008</b> , 46, 648-54	5.9	4
48	ITIM-dependent endocytosis of CD33-related Siglecs: role of intracellular domain, tyrosine phosphorylation, and the tyrosine phosphatases, Shp1 and Shp2. <i>Journal of Leukocyte Biology</i> , <b>2008</b> , 83, 200-11	6.5	52
47	Cutaneous graft-versus-host disease: a guide for the dermatologist. <i>Dermatology</i> , <b>2008</b> , 216, 287-304	4.4	81
46	Simultaneously targeting CD45 significantly increases cytotoxicity of the anti-CD33 immunoconjugate, gemtuzumab ozogamicin, against acute myeloid leukemia (AML) cells and improves survival of mice bearing human AML xenografts. <i>Blood</i> , <b>2008</b> , 111, 4813-6	2.2	13
45	Phosphorylated ITIMs enable ubiquitylation of an inhibitory cell surface receptor. <i>Traffic</i> , <b>2008</b> , 9, 267-79	5.7	26
44	CD33 expression and P-glycoprotein-mediated drug efflux inversely correlate and predict clinical outcome in patients with acute myeloid leukemia treated with gemtuzumab ozogamicin monotherapy. <i>Blood</i> , <b>2007</b> , 109, 4168-70	2.2	150
43	Functional expression of the CD163 scavenger receptor on acute myeloid leukemia cells of monocytic lineage. <i>Journal of Leukocyte Biology</i> , <b>2006</b> , 79, 312-8	6.5	27
42	Acute, life-threatening hypoglycemia associated with haloperidol in a hematopoietic stem cell transplant recipient. <i>Bone Marrow Transplantation</i> , <b>2006</b> , 37, 109-10	4.4	5
41	Relationship between CD33 Expression, P-Glycoprotein-Mediated Drug Efflux, and Clinical Outcome in Patients Treated in Phase II Trials with Gemtuzumab Ozogamicin Monotherapy.. <i>Blood</i> , <b>2006</b> , 108, 2324-2324	2.2	1
40	Influence of CD33 expression levels and ITIM-dependent internalization on gemtuzumab ozogamicin-induced cytotoxicity. <i>Blood</i> , <b>2005</b> , 105, 1295-302	2.2	127
39	PK11195, a peripheral benzodiazepine receptor (pBR) ligand, broadly blocks drug efflux to chemosensitize leukemia and myeloma cells by a pBR-independent, direct transporter-modulating mechanism. <i>Blood</i> , <b>2005</b> , 106, 3584-93	2.2	47
38	Letter regarding article by Vita et al, "serum myeloperoxidase levels independently predict endothelial dysfunction in humans". <i>Circulation</i> , <b>2005</b> , 111, e167-8; author reply e167-8	16.7	1
37	Images in clinical medicine. Vitiligo and pernicious anemia. <i>New England Journal of Medicine</i> , <b>2004</b> , 350, 2698	59.2	4
36	Functional tetrahydrobiopterin synthesis in human platelets. <i>Circulation</i> , <b>2004</b> , 110, 186-92	16.7	20
35	Breast cancer resistance protein (BCRP/ABCG2) does not confer resistance to gemtuzumab ozogamicin and calicheamicin-gamma1 in acute myeloid leukemia cells. <i>Leukemia</i> , <b>2004</b> , 18, 1914-7	10.7	10
34	The peripheral benzodiazepine receptor ligand PK11195 overcomes different resistance mechanisms to sensitize AML cells to gemtuzumab ozogamicin. <i>Blood</i> , <b>2004</b> , 103, 4276-84	2.2	76



33	Fatal necrotizing fasciitis due to <i>Streptococcus pneumoniae</i> after renal transplantation. <i>Nephrology Dialysis Transplantation</i> , <b>2003</b> , 18, 195-7	4.3	13
32	Expression of the hemoglobin scavenger receptor (CD163/HbSR) as immunophenotypic marker of monocytic lineage in acute myeloid leukemia. <i>Blood</i> , <b>2003</b> , 101, 3755-6	2.2	38
31	Multidrug resistance protein attenuates gemtuzumab ozogamicin-induced cytotoxicity in acute myeloid leukemia cells. <i>Blood</i> , <b>2003</b> , 102, 1466-73	2.2	109
30	Critical role of interleukin-1beta for transcriptional regulation of endothelial 6-pyruvoyltetrahydropterin synthase. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , <b>2003</b> , 23, e50-3	9.4	18
29	Drotrecogin alfa (activated) for the treatment of meningococcal purpura fulminans. <i>Intensive Care Medicine</i> , <b>2003</b> , 29, 337	14.5	14
28	Safety of lumbar puncture for adults with acute leukemia and restrictive prophylactic platelet transfusion. <i>Annals of Hematology</i> , <b>2003</b> , 82, 570-3	3	59
27	Rapid detection of pathogenic fungi from clinical specimens using LightCycler real-time fluorescence PCR. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , <b>2003</b> , 22, 558-60	5.3	58
26	Impairment of blood rheology by cholestatic jaundice in human beings. <i>Translational Research</i> , <b>2003</b> , 142, 391-8		4
25	Fatal hepatic veno-occlusive disease associated with terbinafine in a liver transplant recipient. <i>Journal of Hepatology</i> , <b>2003</b> , 38, 373-4	13.4	8
24	Acute severe anaemia in an elderly patient with hereditary sphaerocytosis. <i>Postgraduate Medical Journal</i> , <b>2003</b> , 79, 244, 246	2	
23	HMG-CoA reductase inhibitors are associated with decreased serum neopterin levels in stable coronary artery disease. <i>Clinical Chemistry and Laboratory Medicine</i> , <b>2003</b> , 41, 1314-9	5.9	21
22	Continuous infusion of escalated doses of amphotericin B deoxycholate: an open-label observational study. <i>Clinical Infectious Diseases</i> , <b>2003</b> , 36, 943-51	11.6	99
21	Gemcitabine-associated hemolytic-uremic syndrome. <i>American Journal of Kidney Diseases</i> , <b>2002</b> , 40, E16	7.4	58
20	Metastatic squamous cell carcinoma with marked blood eosinophilia and elevated serum interleukin-5 levels. <i>Experimental Hematology</i> , <b>2002</b> , 30, 1-2	3.1	12
19	Life-threatening thrombocytopenia associated with acute Epstein-Barr virus infection in an older adult. <i>Annals of Hematology</i> , <b>2002</b> , 81, 672-5	3	13
18	Near-fatal arrhythmia caused by hyperkalaemia. <i>British Heart Journal</i> , <b>2002</b> , 88, 578		2
17	Acidosis induced by lactate, pyruvate, or HCl increases blood viscosity. <i>Journal of Critical Care</i> , <b>2002</b> , 17, 68-73	4	17
16	Tetrahydrobiopterin in the vascular system. <i>Pteridines</i> , <b>2001</b> , 12, 93-120	0.6	5

15	Effects of high-altitude exposure on vascular endothelial growth factor levels in man. <i>European Journal of Applied Physiology</i> , <b>2001</b> , 85, 113-7	3.4	48
14	Bone marrow involvement in Whipple® disease: rarely reported, but really rare?. <i>British Journal of Haematology</i> , <b>2001</b> , 112, 677-9	4.5	21
13	Commercial taxane formulations induce stomatocytosis and increase blood viscosity. <i>British Journal of Pharmacology</i> , <b>2001</b> , 134, 1207-14	8.6	23
12	Establishment and characterization of an arsenic-sensitive monoblastic leukaemia cell line (SigM5). <i>British Journal of Haematology</i> , <b>2000</b> , 109, 396-404	4.5	7
11	Influence of parathyroid hormone, calcitonin, 1,25(OH) <sub>2</sub> cholecalciferol, calcium, and the calcium ionophore A23187 on erythrocyte morphology and blood viscosity. <i>Translational Research</i> , <b>2000</b> , 135, 347-52		6
10	Systemic tetrahydrobiopterin (BH <sub>4</sub> ) levels and coronary artery disease. <i>Cardiology</i> , <b>2000</b> , 94, 265-6	1.6	4
9	Pharmacological concentrations of arginine influence human whole blood viscosity independent of nitric oxide synthase activity in vitro. <i>Biochemical and Biophysical Research Communications</i> , <b>2000</b> , 269, 687-91	3.4	10
8	Influence of nitrovasodilators and endothelin-1 on rheology of human blood in vitro. <i>British Journal of Pharmacology</i> , <b>1999</b> , 128, 744-50	8.6	11
7	The nitric oxide synthase cofactor tetrahydrobiopterin reduces allograft ischemia-reperfusion injury after lung transplantation. <i>Journal of Thoracic and Cardiovascular Surgery</i> , <b>1999</b> , 118, 726-32	1.5	38
6	Reactivation of herpesvirus infections after vaccinations?. <i>Lancet, The</i> , <b>1999</b> , 353, 810	4.0	71
5	Primary pleomorphic adenoma of the external auditory canal diagnosed by fine needle aspiration cytology. A case report. <i>Acta Cytologica</i> , <b>1999</b> , 43, 489-91	3	14
4	Induction of tetrahydrobiopterin synthesis in human umbilical vein smooth muscle cells by inflammatory stimuli. <i>Immunology Letters</i> , <b>1998</b> , 60, 13-7	4.1	13
3	Inhalation of the nitric oxide synthase cofactor tetrahydrobiopterin in healthy volunteers. <i>American Journal of Respiratory and Critical Care Medicine</i> , <b>1997</b> , 156, 2006-10	10.2	6
2	Untroubled musical judgement of a performing organist during early epileptic seizure of the right temporal lobe. <i>Neuropsychologia</i> , <b>1997</b> , 35, 45-51	3.2	13
1	Differential regulation of constitutive and inducible nitric oxide production by inflammatory stimuli in murine endothelial cells. <i>Biochemical and Biophysical Research Communications</i> , <b>1994</b> , 202, 450-5	3.4	44